Drug intelligence / Profile preview

IN036

Development stage: Preclinical
Lead developer: Innorna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

IN036 is an investigational mRNA-based therapeutic being developed by InnoRNA Biotech for the treatment of systemic lupus erythematosus (SLE). The drug utilizes InnoRNA's proprietary lipid nanoparticle (LNP) platform for systemic delivery. While the specific molecular target and precise mechanism of action remain undisclosed, it is designed as a novel mRNA candidate to modulate the immune response associated with SLE and potentially other autoimmune diseases. As of early 2026, the program is in the IND-enabling stage of development.

Beyond the preview

Go deeper on IN036.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN036.

Explore the full profile